Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase I/IIa, Open-label, Dose Ranging Study to Evaluate the Safety, Tolerability and Immunogenicity of GLS-5300, Administered ID Followed by CELLECTRA 2000 (Electroporation, EP)

Trial Profile

Phase I/IIa, Open-label, Dose Ranging Study to Evaluate the Safety, Tolerability and Immunogenicity of GLS-5300, Administered ID Followed by CELLECTRA 2000 (Electroporation, EP)

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 08 Nov 2018

At a glance

  • Drugs GLS 5300 (Primary)
  • Indications Middle East respiratory syndrome coronavirus
  • Focus Adverse reactions
  • Sponsors GeneOne Life Science
  • Most Recent Events

    • 08 Nov 2018 According to an Inovio Pharmaceuticals media release, interim results from this trial are expecte in 2019.
    • 05 Sep 2018 According to an Inovio Pharmaceuticals media release, Leveraging results from this study, Inovio expects to advance its MERS vaccine into a Phase 2 field trial in the Middle East in 2019 with CEPI funding.
    • 05 Sep 2018 According to an Inovio Pharmaceuticals media release, Status changed from planning to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top